Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients ...Middle East

-- ASC10 is an oral double prodrug that is rapidly and completely converted in vivo into the active metabolite ASC10-A, which is the same active metabolite of molnupiravir -- Ascletis has filed multiple patent applications for ASC10 and its use globally. Compared with molnupiravir, ASC10...

Hence then, the article about ascletis announces fda clearance of oral rdrp inhibitor asc10 to conduct a randomized placebo controlled phase ib study in mild to moderate covid 19 patients was published today ( Wednesday 03/08/2022 - 12:08 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients )

Also on site :

• I Came Home Early From a Destination Wedding. What I Found In My House Could Tear My Family Apart.
• What the US strike in Venezuela means for gas prices and the largest proven oil reserve on the planet
• Ukraine-Russia war latest: Zelensky and Starmer discuss how to spend billions seized from Abramovich after Chelsea sale